TRDA — Entrada Therapeutics Cashflow Statement
0.000.00%
Last trade - 00:00- $350.31m
- -$69.69m
- $210.78m
- 67
- 96
- 56
- 86
Annual cashflow statement for Entrada Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | PROSPECTUS | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -26.5 | -51.2 | -94.6 | -6.68 | 65.6 |
| Depreciation | |||||
| Non-Cash Items | 0.345 | 2.6 | 10 | 7.33 | 7.9 |
| Unusual Items | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | 0.282 | -3.42 | -11.1 | 136 | -119 |
| Change in Accounts Receivable | |||||
| Change in Prepaid Expenses | |||||
| Change in Other Assets | |||||
| Change in Accounts Payable | |||||
| Change in Accrued Expenses | |||||
| Change in Taxes Payable | |||||
| Change in Other Liabilities | |||||
| Cash from Operating Activities | -25.6 | -50.9 | -93.8 | 140 | -41.6 |
| Capital Expenditures | -2.33 | -4.58 | -2.89 | -5.61 | -3.16 |
| Purchase of Fixed Assets | |||||
| Other Investing Cash Flow Items | 0.007 | — | -146 | -133 | -24.6 |
| Sale of Fixed Assets | |||||
| Sale/Maturity of Investment | |||||
| Purchase of Investments | |||||
| Cash from Investing Activities | -2.32 | -4.58 | -149 | -138 | -27.8 |
| Net Issuance / Retirement of Stock | |||||
| Cash from Financing Activities | 50.1 | 307 | 0.479 | 21 | 103 |
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | 22.2 | 252 | -242 | 22.4 | 33.6 |